Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy

Background/Aim. Dysregulation of fatty acid (FA) metabolism is recognized as a component malignant trans-formation in many cancers, including breast cancer (BC), and often related to disease progression prognosis. Adjuvant endocrine BC therapy using aromatase inhibitors may also influence FA metabolism. Thus, the aim our study was compare plasma total lipids status newly diagnosed postmenopausal patients with women receiving at least 2 years after completing chemotherapy healthy women. Methods. The included 17 (ND group) 21 inhibitor ending (AI group), while 15 apparently without family history BC, comparable age body mass index, served control group. Results. In both patient groups, we found significantly lower levels vaccenic (18:1n-7), alpha-linolenic (18:3n-3), gamma-linolenic (GLA, 18:3n-6), docosapentae-noic (22:5n-3), higher level di-homo-gamma-linolenic (20:3n-6), when compared On other hand, stearic (18:0) observed only AI patients, linoleic (18:2n-6) ND than Reduced estimated activities D6 D5 desaturases were groups Conclusion. Our results indicate that profiles diagnosed, untreated are very similar those cured who underwent all sessions received for two years. Additionally, according results, their markedly differ from Therefore, supplementation omega-3 GLA could have beneficial effects these further studies should address potential clinical benefits supplementation.